Vanda Pharmaceuticals ( (VNDA) ) has released its Q1 earnings. Here is a breakdown of the information Vanda Pharmaceuticals presented to its investors.
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company that focuses on developing and commercializing innovative therapies to address unmet medical needs, particularly in the field of central nervous system disorders.
In its first quarter of 2025, Vanda Pharmaceuticals reported a 5% increase in total net product sales, reaching $50 million, driven by the growth of its key products, Fanapt and HETLIOZ. The company also highlighted significant advancements in its drug development pipeline, including new drug applications for Bysanti and Tradipitant.
Fanapt, approved for bipolar I disorder, saw a 14% increase in prescriptions compared to the previous year, while HETLIOZ maintained its market share despite generic competition. However, PONVORY experienced an 18% decline in sales. Vanda’s net loss widened to $29.5 million, largely due to increased expenses related to its licensing agreement for imsidolimab and expanded commercial activities.
Looking forward, Vanda aims to continue its growth trajectory with a robust pipeline, including upcoming regulatory submissions and clinical trials. The company maintains its revenue guidance for 2025, anticipating total revenues between $210 and $250 million, and aims to end the year with cash reserves between $280 and $320 million.